John LaMattian, former head of Pfizer R&D, says industry mergers have harmed R&D efforts
John L. LaMattina, the former President of Pfizer Global Research and Development, has just published an article in Nature that looks at the impact of drug company mergers and increased industry concentration on R&D. Among his conclusions: the “impact on the R&D of the organizations involved has been devastating.”
http://www.nature.com/nrd/journal/v10/n8/full/nrd3514.html
COMMENT
NATURE REVIEWS | DRUG DISCOVERY VOLUME 10 | AUGUST 2011 | 559
The impact of mergers on pharmaceutical R&D